Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

Azenta (AZTA) received full early repayment of the $35 million secured vendor loan related to the sale of B Medical Systems to Thelema S.à r.l.

Rhea-AI Summary

Azenta (AZTA) received full early repayment of the $35 million secured vendor loan related to the sale of B Medical Systems to Thelema S.à r.l.

The loan was provided by Azenta Germany GmbH, a wholly owned subsidiary, under a Vendor Loan Agreement as part of the transaction that closed on July 1, 2026. The loan, secured by a pledge over B Medical Systems’ equity interests, has been repaid in full together with all accrued interest, and the related share pledge has been released. With this repayment, Azenta has now received in cash the entire $63 million purchase price for B Medical Systems, and the company states that the credit exposure associated with the transaction has been retired.

Positive

• $35 million vendor loan repaid in full before maturity, including accrued interest
• Azenta has now received the entire $63 million B Medical Systems purchase price in cash
• Release of share pledge over B Medical Systems equity removes transaction-related collateral arrangements
• Company states credit exposure from the B Medical Systems divestiture has been retired

Negative

• None.

Market Context

The August 4 earnings report was followed by AZTA's 5.61% gain, a platform precedent for positive co...

Analysis

The August 4 earnings report was followed by AZTA's 5.61% gain, a platform precedent for positive company news. This repayment confirmed cash realization; moderate short positioning remained a risk factor to monitor.

Key Figures

Vendor loan repayment: $35 million Transaction closing date: July 1, 2026 Purchase price received: $63 million

3 metrics

Vendor loan repayment $35 million Repaid in full prior to maturity

Transaction closing date July 1, 2026 Sale of B Medical Systems

Purchase price received $63 million Entire purchase price received in cash

Historical Context

5 past events · Latest: Aug 24 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 24	Leadership transition	Negative	-12.1%	CEO resignation and interim leadership appointment prompted a 12.09% decline.
Aug 04	Q3 earnings	Positive	+5.6%	Revenue growth and quarterly results were followed by a 5.61% gain.
Jul 30	Leadership transition	Positive	+1.8%	Cabot's planned succession announcement coincided with a 1.84% increase.
Jul 22	Earnings call notice	Neutral	+4.2%	Conference call scheduling preceded a 4.2% increase without reported results.
Jul 08	B Medical sale	Positive	-3.4%	Sale completion preceded a 3.39% decline despite the fixed cash purchase price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive or informational announcements produced mixed reactions, including a -3.39% response to the B Medical sale and +5.61% after third-quarter earnings.

Key Terms

secured vendor loan, vendor loan agreement, share pledge

3 terms

secured vendor loan financial

"received repayment in full, prior to maturity, of the $35 million secured vendor loan"

A secured vendor loan is financing provided by a seller or supplier to a buyer where the loan is backed by collateral—usually assets related to the sale such as inventory, equipment, or accounts receivable. It works like the seller acting as a bank for part of the purchase price, and the security gives the lender a legal claim on specified assets if the borrower fails to repay. Investors care because it changes a company’s debt mix, affects repayment priority in insolvency, and can influence liquidity and risk profiles.

vendor loan agreement financial

"entered into a Vendor Loan Agreement with Thelema S.à r.l."

A vendor loan agreement is a deal where the seller of a business or assets acts like a lender, letting the buyer pay part of the purchase price over time instead of all up front. Think of it as the seller carrying a portion of the mortgage; it matters to investors because it affects the cash flows and credit risk of both parties — the seller keeps exposure to the buyer’s performance, and the buyer gets cheaper or easier financing that can change balance-sheet strength and future returns.

share pledge financial

"the share pledge securing the loan has been released"

A share pledge is a legal arrangement in which a shareholder uses their stock as collateral for a loan, giving the lender a security interest in those shares and the right to seize, transfer, or sell them if the borrower defaults. It matters to investors because pledged shares can lead to sudden sales, shifts in voting control, or changes in ownership concentration—think of it like pawning a valuable item that the lender can sell if the borrower cannot repay.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Sept. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l.

As part of the transaction, which closed on July 1, 2026, Azenta Germany GmbH, a wholly owned subsidiary of Azenta, Inc., entered into a Vendor Loan Agreement with Thelema S.à r.l., pursuant to which Azenta Germany GmbH provided a secured term loan to Thelema S.à r.l. in an aggregate principal amount of $35 million. The vendor loan, which was secured by a pledge over the equity interests of B Medical Systems, has been repaid in full prior to maturity, together with all accrued interest, and the share pledge securing the loan has been released. With the repayment of the vendor loan, Azenta has now received in cash the entire $63 million purchase price for B Medical Systems.

"The repayment of the vendor loan completes the divestiture of B Medical Systems," said Dr. Martin D. Madaus, Interim President and Chief Executive Officer. "Azenta has now received the entire purchase price in cash, and the credit exposure associated with the transaction has been retired, supporting our disciplined approach to capital allocation."

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Azenta's capital allocation strategy and the use of proceeds from the sale of B Medical Systems. These forward-looking statements are based on management's current expectations and are subject to known and unknown risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially include, among others, general economic and market conditions, the Company's ability to execute its strategic initiatives and capital allocation plans, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Although the Company's forward-looking statements reflect the good faith judgment of its management, they are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Forward-looking statements speak only as of the date they are made, and, except as required by applicable law, Azenta undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.

INVESTOR CONTACT for Azenta Life Sciences:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Maria Isabel Cuartas
Manager, Investor Relations
ir@azenta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/azenta-receives-full-repayment-of-35-million-vendor-loan-related-to-sale-of-b-medical-systems-302869687.html

SOURCE Azenta

FAQ

What did Azenta (AZTA) announce about the B Medical Systems vendor loan?

Azenta announced that the $35 million secured vendor loan provided to Thelema S.à r.l. in connection with the sale of B Medical Systems has been repaid in full before maturity, including all accrued interest, and the related share pledge over B Medical Systems’ equity has been released.

How much cash has Azenta (AZTA) received from the sale of B Medical Systems?

Azenta has now received in cash the entire $63 million purchase price for B Medical Systems. This total includes the early repayment in full of the $35 million secured vendor loan plus previously received cash consideration from the July 1, 2026 transaction closing.

Who borrowed the $35 million vendor loan from Azenta (AZTA) in the B Medical Systems sale?

The borrower under the $35 million secured vendor loan was Thelema S.à r.l. The loan was extended by Azenta Germany GmbH, a wholly owned subsidiary of Azenta, as part of the purchase price financing for the acquisition of B Medical Systems.

How was the Azenta (AZTA) vendor loan related to B Medical Systems secured?

The vendor loan was secured by a pledge over the equity interests of B Medical Systems. Following the full repayment of the $35 million principal and accrued interest, the share pledge that secured the loan has been released.

What does the vendor loan repayment mean for Azenta (AZTA) shareholders?

With the repayment of the $35 million vendor loan, Azenta has received the full $63 million B Medical Systems purchase price in cash. The company also states that the credit exposure associated with this divestiture has been retired, aligning with its described disciplined capital allocation approach.